Incannex Healthcare Limited (IXHL)
USD 0.13
(-0.15%)
USD 0.13
(-0.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 12 Thousand USD | 0.0% |
| 2023 | 1.01 Million AUD | 29.59% |
| 2022 | 782.38 Thousand AUD | -45.12% |
| 2021 | 1.42 Million AUD | 243.03% |
| 2020 | 415.62 Thousand AUD | -64.73% |
| 2019 | 1.17 Million AUD | 16.42% |
| 2018 | 1.01 Million AUD | 258.89% |
| 2017 | 282.04 Thousand AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | -100.0% |
| 2013 | 35.73 Thousand AUD | -46.12% |
| 2012 | 66.31 Thousand AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 26.18 Thousand AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 12 Thousand USD | 0.0% |
| 2024 Q3 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q4 | 1.01 Million USD | 0.0% |
| 2023 FY | 1.01 Million AUD | 29.59% |
| 2022 FY | 782.38 Thousand AUD | -45.12% |
| 2022 Q4 | 782.38 Thousand USD | 0.0% |
| 2021 FY | 1.42 Million AUD | 243.03% |
| 2020 FY | 415.62 Thousand AUD | -64.73% |
| 2019 FY | 1.17 Million AUD | 16.42% |
| 2018 FY | 1.01 Million AUD | 258.89% |
| 2017 FY | 282.04 Thousand AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q3 | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2014 Q2 | 8933.75 AUD | 0.0% |
| 2014 FY | - AUD | -100.0% |
| 2014 Q3 | - AUD | -100.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q1 | 8933.75 AUD | 0.0% |
| 2013 Q4 | 8933.75 AUD | 0.0% |
| 2013 Q1 | 16.57 Thousand AUD | 0.0% |
| 2013 Q2 | 16.57 Thousand AUD | 0.0% |
| 2013 FY | 35.73 Thousand AUD | -46.12% |
| 2013 Q3 | 8933.75 AUD | -46.11% |
| 2012 FY | 66.31 Thousand AUD | 0.0% |
| 2012 Q4 | 16.57 Thousand AUD | 0.0% |
| 2012 Q3 | 16.57 Thousand AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q1 | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2011 Q3 | - AUD | -100.0% |
| 2011 Q1 | 6545.25 AUD | 0.0% |
| 2011 Q2 | 6545.25 AUD | 0.0% |
| 2010 Q3 | 6545.25 AUD | 0.0% |
| 2010 Q4 | 6545.25 AUD | 0.0% |
| 2010 FY | 26.18 Thousand AUD | 0.0% |
| 2010 Q1 | - AUD | 0.0% |
| 2010 Q2 | - AUD | 0.0% |
| 2009 Q1 | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 Q2 | - AUD | 0.0% |
| 2009 Q3 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 Q3 | - AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.998% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 99.976% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.998% |
| Cosmos Health Inc. | 53.37 Million USD | 99.978% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 98.885% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 99.99% |
| Cronos Group Inc. | 88.84 Million USD | 99.986% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 99.991% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 99.95% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 99.95% |
| SCYNEXIS, Inc. | 140.14 Million USD | 99.991% |
| Safety Shot Inc | 202.67 Thousand USD | 94.079% |
| Theratechnologies Inc. | 81.76 Million USD | 99.985% |
| Alpha Teknova, Inc. | 36.68 Million USD | 99.967% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 99.963% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.998% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 99.906% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.995% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.997% |
| Radius Health, Inc. | 2.88 Billion USD | 100.0% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 99.378% |
| Alvotech | 91.43 Million USD | 99.987% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.997% |
| SIGA Technologies, Inc. | 139.91 Million USD | 99.991% |
| Shineco, Inc. | 9.8 Million USD | 99.878% |
| Silver Spike Investment Corp. | 11.72 Million USD | 99.898% |
| Journey Medical Corporation | 79.18 Million USD | 99.985% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 99.794% |
| Embecta Corp. | 1.12 Billion USD | 99.999% |
| Harrow Health, Inc. | 130.19 Million USD | 99.991% |
| Procaps Group, S.A. | 409.92 Million USD | 99.997% |
| Biofrontera Inc. | 34.07 Million USD | 99.965% |
| DURECT Corporation | 8.54 Million USD | 99.86% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.998% |
| OptiNose, Inc. | 70.98 Million USD | 99.983% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 99.816% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 99.997% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 99.97% |
| ProPhase Labs, Inc. | 44.38 Million USD | 99.973% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.999% |
| Procaps Group S.A. | 409.92 Million USD | 99.997% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 99.078% |
| Viatris Inc. | 15.42 Billion USD | 100.0% |
| Rockwell Medical, Inc. | 83.61 Million USD | 99.986% |
| Aytu BioPharma, Inc. | 81 Million USD | 99.985% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.998% |
| PetIQ, Inc. | 1.1 Billion USD | 99.999% |
| Talphera, Inc. | 651 Thousand USD | 98.157% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.999% |
| Alimera Sciences, Inc. | 80.75 Million USD | 99.985% |
| Assertio Holdings, Inc. | 152.06 Million USD | 99.992% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 99.957% |
| Hempacco Co., Inc. | 4.04 Million USD | 99.703% |
| Alvotech | 91.43 Million USD | 99.987% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.999% |
| Kamada Ltd. | 144.75 Million USD | 99.992% |
| Currenc Group, Inc. | 53.25 Million USD | 99.977% |
| Indivior PLC | 1.09 Billion USD | 99.999% |
| Evoke Pharma, Inc. | 5.18 Million USD | 99.768% |
| Flora Growth Corp. | 76.07 Million USD | 99.984% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 98.885% |
| Evolus, Inc. | 202.08 Million USD | 99.994% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.999% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.998% |
| Akanda Corp. | 2.16 Million USD | 99.444% |